Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)

75

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS® (brentuximab vedotin) clinical development program at the 24th Annual Congress of the European Hematology Association (EHA) taking place June 13-16 in Amsterdam; and the International Conference on Malignant Lymphoma (ICML) from June 18-22 in Lugano. Updated analyses from clinical trials evaluating ADCETRIS in combination with Opdivo® (nivolumab), as well as encore analyses from the pha http://www.businesswire.com/news/home/20190612005283/en/Seattle-Genetics-Announces-Multiple-ADCETRIS%C2%AE-Brentuximab-Vedotin/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==